Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeksMarch 21, 2015Psoriasis
Halting biologics before surgery tied to flares in psoriasis, psoriatic arthritisMarch 13, 2015Psoriasis
Disease Burden and Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Results From National Psoriasis Foundation Panel Surveys March 11, 2015Psoriasis
Interleukin-23 inhibition with tildrakizumab achieves significant psoriasis improvementsMarch 9, 2015Psoriasis
Ixekizumab improves lesions in patients with chronic plaque psoriasis after 20 weeksFebruary 24, 2015Psoriasis
